Sampo plc
Sampo plc’s share buybacks 14 August 2025
Sampo plc’s share buybacks 14 August 2025
Sampo plc, stock exchange release, 15 August 2025 at 8:30 am EEST
Sampo plc’s share buybacks 14 August 2025
On 14 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:
Sampo plc’s share buybacks | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares* | Market (MIC Code) |
3,865 | 9.85 | AQEU | |
110,513 | 9.85 | CEUX | |
23,565 | 9.85 | TQEX | |
189,452 | 9.85 | XHEL | |
TOTAL | 327,395 | 9.85 |
* rounded to two decimals
On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 7 August 2025, is based on the authorisation granted by Sampo's Annual General Meeting on 23 April 2025.
After the disclosed transactions, the company owns in total 1,974,201 Sampo A shares representing 0.07 per cent of the total number of shares in Sampo plc.
Details of each transaction are included as an appendix of this announcement.
On behalf of Sampo plc,
Morgan Stanley
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG30.8.2025 17:00:00 CEST | Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
F. Hoffmann-La Roche Ltd30.8.2025 16:30:00 CEST | Press release
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
CGTN30.8.2025 11:44:44 CEST | Pressemeddelelse
CGTN: Arven efter Flying Tigers fejres for at styrke det varige bånd mellem Kina og USA
Sanofi Winthrop Industrie29.8.2025 23:50:03 CEST | Press release
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Northland Power Inc.29.8.2025 23:15:13 CEST | Press release
Northland Announces Reset Dividend Rate on Its Cumulative Rate Reset Preferred Shares, Series 1 & Series 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom